ClinicalTrials.gov
public full text
Public Domain
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zoledronate for bone metastases. This clinical trial includes a dose-escalation phase and dose-expansion phase to assess the safety and preliminary efficacy of treatment with autologous T cells genetically modified to express Prostate stem cell antigen.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer#162466
- Pilot Window of Opportunity Trial (POET)#1102498
- PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma#825405
- Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy#839587
- Coordinated circulating and tissue-based T cell responses precede xenograft rejection 2308959#485009
Record · ID 1008641
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive